TerminatedPhase 3NCT03482752
Safety Extension Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis
Studying Autoimmune pulmonary alveolar proteinosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Savara Inc.
- Principal Investigator
- Francesco Bonella, Prof.Interstitial and Rare Lung Disease Unit, Ruhrlandklinik University Hospital, Essen, Germany
- Intervention
- Molgramostim(drug)
- Enrollment
- 60 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2021
Study locations (13)
- Dept. Of Respiratory Diseases & Allergy, Aarhus, Denmark
- CHU Rennes Hospital Pontchaillou, Service de Pneumologie, Rennes, France
- Ruhrlandklinik Essen Westdeutsches Lungenzentrum am Universitätsklinikum Essen GmbH, Essen, Germany
- Asklepios Fachkliniken München - Gauting Klinik für Pneumologie, Gauting, Germany
- Thoraxklinik am Universitätsklinikum Heidelberg Abteilung für Pneumologie und Beatmungsmedizin, Heidelberg, Germany
- Universitätsklinikum Schleswig-Holstein Zentralklinikum Lübeck Medizinische Klinik III - Pneumologie, Lübeck, Germany
- Attikon University Hospital 2nd Pulmonary Department Athens Medical School National and Kapodistrian University of Athens, Athens, Greece
- Rabin Medical Center Institute of Pulomonary Medicine, Tel Aviv, Israel
- S.C. Pneumologia Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
- St. Antonius Hospital, Nieuwegein, Netherlands
- Pavlov first Saint Petersburg State Medical Univerisity, Saint Petersburg, Russia
- Yedikule Pulmonary Diseases and Pulmonary Surgery Training and Research Hospital, Istanbul, Turkey (Türkiye)
- Dept. Of Intensive Care Unit Royal Brompton Hospital London, London, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03482752 on ClinicalTrials.govOther trials for Autoimmune pulmonary alveolar proteinosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT06431776Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).Savara Inc.
- RECRUITINGPHASE4NCT07200544Meloxicam in Mohs Micrographic SurgeryUniversity of Oklahoma
- RECRUITINGPHASE4NCT07102641Post-cesarean Analgesia: Comparing Effectiveness of Staggered v. Simultaneous TherapiesThomas Jefferson University
- ACTIVE NOT RECRUITINGPHASE2NCT06111846Study of Human Bone Marrow Mesenchymal Stem Cells in APAPJiuzhitang Maker (Beijing) Cell Technology Co.,Ltd.
- RECRUITINGPHASE4NCT05425355Intravenous vs Oral Acetaminophen in Postoperative Hip Fracture Adult PatientsUniversity Health Network, Toronto
- ACTIVE NOT RECRUITINGPHASE3NCT04544293Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)Savara Inc.
- RECRUITINGPHASE4NCT03759028Supracondylar Post-Operative Pain StudyUniversity of California, Los Angeles
See all trials for Autoimmune pulmonary alveolar proteinosis →